Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical bevacizumab eye drops versus intra-meibomian gland bevacizumab injection for meibomian gland dysfunction
TCTR20201102001Phase 3Recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in meibomian gland dysfunction (MGD), sponsored by Ratchadaphiseksomphot Endowment Fund. Started Sep 2020; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on TCTR20201102001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201102001.